newsfilter
← Latest News
Business Wire·

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

  • Glaukos Corporation announced the commercial availability of Epioxa™ HD & Epioxa™, the first FDA-approved incision-free topical drug therapy for keratoconus.
  • The therapy is an epithelium-on corneal cross-linking treatment designed to reduce pain, minimize recovery time, & improve patient comfort compared to traditional procedures.
  • Epioxa functions as a photoenhancer catalyzed by enriched oxygen & light when used in conjunction with the O2n™ System & Boost Goggles®.
  • It is indicated for adults & pediatric patients aged 13 years & older with keratoconus.
  • Glaukos plans to launch patient support initiatives including a patient access liaison team, co-pay assistance, uninsured assistance, & awareness campaigns to address underdiagnosis.
  • Common adverse reactions include conjunctival hyperaemia (31%), corneal opacity, photophobia, eye pain, & dry eye.
  • The treatment is contraindicated in patients with known hypersensitivity to benzalkonium chloride or in aphakic & pseudophakic patients without a UV-blocking intraocular lens.
  • Epioxa is available for ordering directly from Glaukos or through its specialty pharmaceutical distribution network.